{
    "nct_id": "NCT04292730",
    "official_title": "A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment",
    "inclusion_criteria": "* Willing and able to provide written informed consent prior to performing study procedures (participants ≥ 18 years of age) or assent (participants ≥ 12 and < 18 years of age) prior to performing study procedures. For participants ≥ 12 and < 18 years of age, a parent or legal guardian willing and able to provide written informed consent prior to performing study procedures\n* Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) test ≤ 4 days before randomization\n* Currently hospitalized and requiring medical care for COVID-19\n* Peripheral capillary oxygen saturation (SpO2) > 94% on room air at screening\n* Radiographic evidence of pulmonary infiltrates\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Participation in any other clinical trial of an experimental treatment for COVID-19\n* Concurrent treatment or planned concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS-CoV-2\n* Requiring mechanical ventilation at screening\n* Alanine Aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 X upper limit of normal (ULN)\n* Creatinine clearance < 50 mL/min using the Cockcroft-Gault formula for participants ≥ 18 years of age {Cockcroft 1976} and Schwartz Formula for participants < 18 years of age\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "miscellaneous_criteria": "Key"
}